US20140194370A1 - Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer - Google Patents
Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer Download PDFInfo
- Publication number
- US20140194370A1 US20140194370A1 US14/150,652 US201414150652A US2014194370A1 US 20140194370 A1 US20140194370 A1 US 20140194370A1 US 201414150652 A US201414150652 A US 201414150652A US 2014194370 A1 US2014194370 A1 US 2014194370A1
- Authority
- US
- United States
- Prior art keywords
- agent
- chemoembolic
- selp
- injectable
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 22
- 229920002549 elastin Polymers 0.000 title claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 title abstract description 50
- 201000011510 cancer Diseases 0.000 title abstract description 9
- 229920000642 polymer Polymers 0.000 title description 18
- 230000010102 embolization Effects 0.000 title description 12
- 230000010109 chemoembolization Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 81
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 23
- 229920001577 copolymer Polymers 0.000 claims abstract description 19
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 19
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 18
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 18
- 230000003073 embolic effect Effects 0.000 claims description 31
- 239000000017 hydrogel Substances 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 15
- 239000002872 contrast media Substances 0.000 claims description 13
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
- 102000005741 Metalloproteases Human genes 0.000 claims description 5
- 108010006035 Metalloproteases Proteins 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000010188 recombinant method Methods 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 15
- 239000007924 injection Substances 0.000 abstract description 15
- 210000005166 vasculature Anatomy 0.000 abstract description 12
- 108010042076 SELP 815K Proteins 0.000 description 35
- 239000000243 solution Substances 0.000 description 29
- 239000000203 mixture Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- 238000009472 formulation Methods 0.000 description 19
- 210000001367 artery Anatomy 0.000 description 16
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 15
- 102100023472 P-selectin Human genes 0.000 description 15
- 101000873420 Simian virus 40 SV40 early leader protein Proteins 0.000 description 15
- 108010003427 silk-elastinlike protein 47K Proteins 0.000 description 15
- 239000000499 gel Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 9
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000016942 Elastin Human genes 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940126587 biotherapeutics Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000011521 systemic chemotherapy Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- BWPAACFJSVHZOT-RCBQFDQVSA-N (2s)-1-[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O BWPAACFJSVHZOT-RCBQFDQVSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108700010340 Leishmanolysins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108010069589 glycyl-valyl-glycyl-valyl-proline Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- -1 matrilysins Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000008320 venous blood flow Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
Definitions
- the present disclosure relates generally to the field of treating cancer by blocking tumor vasculature with a protein hydrogel embolic agent that may also include a chemotherapeutic drug.
- the hydrogel may be configured to release chemotherapeutic drug into the tumor at a defined rate.
- FIG. 1A provides the amino acid sequence of two embodiments of SELPs as disclosed herein, SELP-47K and SELP-815K.
- FIG. 1B illustrates the assumed network configuration of the SELPs of FIG. 1A .
- FIGS. 2A , 2 B, and 2 C together, present a schematic depicting TACE treatment in a subject.
- FIG. 2A illustrates the step of gaining vascular access in the subject.
- FIG. 2B illustrates the step of selecting an artery that feeds the tumor for injecting the chemoembolic agent.
- FIG. 2C illustrates the step of administering the chemoembolic to the tumor.
- FIG. 3 depicts a flowchart that defines steps of a proposed method to identify and test a candidate formulation for a chemoembolic as disclosed herein.
- FIG. 4A is a graph that illustrates the viscosity profiles of different concentrations of SELP-815K.
- FIG. 4B illustrates the viscosity of 12% w/w SELP-47K during a thermal profile that simulated transcatheter injection.
- FIG. 4C is a graph that illustrates the gel stiffness of varying concentrations of SELP-815K over time as it forms a hydrogel.
- FIG. 4D is a graph that illustrates the gelation rates of varying concentrations of SELP-47K over time as they form hydrogels at 37° C.
- FIG. 5 is a graph that demonstrates the incorporation of contrast agent into 16% w/w SELP-815K for use in guiding a transarterial catheter during administration of the embolic agent.
- FIGS. 6A , 6 B, and 6 C illustrate the in vitro microfluidic system used to assess the ability of the embolic agent to occlude the microvasculature.
- FIG. 6A depicts the in vitro microfluidic device with simulated blood flowing through the structures that simulate the vasculature.
- FIG. 6B depicts the in vitro microfluidic device of FIG. 6A being injected with SELP-815K solution.
- FIG. 6C depicts the in vitro microfluidic device of FIG. 6B being injected with simulated blood after injected SELP-815K has formed a hydrogel embolism.
- the present disclosure relates generally to the field of embolics and drug delivery methods for treating cancer. More specifically, the present disclosure relates to the use of recombinantly synthesized silk-elastin-like protein (SELP) copolymers to embolize tumor vasculature, including the small vessels such as arterioles.
- SELP solution is an injectable liquid at room temperature and forms a hydrogel in the tumor vasculature at body temperature.
- the material may be loaded with one or more chemotherapeutic drugs which may be released into the tumor from the embolic agent.
- the copolymers may also have matrix metalloprotease cleavage sites engineered into the protein copolymer using recombinant techniques to enable controlled breakdown of the embolic material. This modification provides control over the duration of embolization and controlled release of the chemotherapeutic agent. Therefore, the material may attack the tumor both by depriving it of blood supply and/or by delivering chemotherapeutic compounds.
- Hepatocellular carcinoma is a cancer of the liver which, due to its relative lack of symptoms, is detected at advanced stages in 84% of cases.
- the 1-year survival rate of symptomatic HCC patients is 22% and at 5 years it is 5%.
- the only curative option is surgical liver resection and liver transplantation. The lack of donor livers and the rapid progression of the disease, however, eliminates this option for most patients.
- TACE transcatheter arterial chemoemobolization
- TACE is the recommended first-line treatment option to increase survival times of patients with unresectable HCC
- its effectiveness is dependent on a number of factors. Foremost among these factors is the physical and chemical nature of the embolizing agent. Liquid embolizing agents are the most easily injected through the smallest diameter catheters, consequently accessing the smaller, more tumor-selective arteries. Their drawback, at times, is that they may not be stably maintained in the arteries as liquids after injection as in the case of Lipiodol®, an iodized esterified oil, or as insoluble masses, as in the case of Onyx®, a liquid suspension of polyethylenevinylalcohol dissolved in DMSO.
- Embolizing agents consisting of particulate solids form more stable emboli, but are often more difficult to inject. They may require larger diameter catheters due to their large size (typically 200-1000 ⁇ m diameter particles), which limits the selectivity of the embolization.
- TACE has been used to treat HCC with some success.
- Collateral damage to healthy liver can arise from excessive non-tumor selective embolization or chemotherapeutic toxicity.
- TACE is contraindicated for treatment of patients with multiple tumors (>2 tumors) or large tumors (>3 cm diameter).
- embolization could be more selectively performed and chemotherapeutic delivery better controlled.
- advances in the understanding of the physiology and pharmacology of hepatocellular carcinoma have led to the development of new potential drug therapies targeting the vascularization of HCC tumors.
- these include high molecular weight therapeutics which cannot be effectively delivered using existing embolizing agents.
- An example is the biologic, bevacizumab, an anti-VEGF monoclonal antibody, which has a molecular weight of approximately 149 kD.
- An embolizing agent that is compatible with these drugs and capable of providing sustained delivery of high-molecular weight agents is needed.
- embolic agents composed of the synthetic polymers polyvinyl alcohol (PVA) or ethylene vinyl acetate (EVA) provides a permanent embolization. These polymers are non-degradable and can remain in tissues indefinitely. If an effective occlusion occurs immediately upon embolization and the occlusion is physically maintained (lack of recanalization), then blood flow to the target tissue will be permanently blocked. However, clinical outcomes are seldom clear-cut. After TACE, tumors have been found to respond to treatment for periods of up to several weeks to months, and then resume growth.
- PVA polyvinyl alcohol
- EVA ethylene vinyl acetate
- an embolizing agent must be able to be selectively delivered to tumor arteries where it forms stable arterial occlusions.
- Ideal embolizing agents would likely take the form of a liquid with a viscosity low enough for injection through the smallest endovascular catheters (in some instances ⁇ 500 ⁇ m inner diameter), enabling its flow into the smallest arteries, but high enough to restrict its flow through the capillaries and into systemic circulation. After injection, such liquid embolizing agents would transition to a solid hydrogel with enough physical strength to prevent its wash-out into the venous blood flow.
- Such liquid embolizing agents and their hydrogels would also, ideally, be completely aqueous and compatible with the delivery of anti-cancer drugs, including high-molecular-weight biotherapeutics, which are unable to be effectively delivered with current drug-eluting embolizing agents.
- Localized delivery to the tumor is important because therapeutics that effectively treat HCC and other tumors also often have undesired effects on other tissues.
- new anti-angiogenic agents suppress tumor revascularization and regrowth, but may also suppress wound healing responses in patients with underlying wound pathologies such as extremity wounds in diabetic patients.
- Potent anti-proliferative drugs that target cells experiencing hypoxia could have significant effects on embolized liver tumors, however, they may also exacerbate the deterioration of heart and vascular tissues in patients with cardiovascular disease. Avoiding the off-target effects of these and other drugs by concentrating and localizing their release by delivering TACE according to the present disclosure could significantly advance new therapeutic options for HCC.
- Novel arterial embolizing agents are disclosed herein which may elute drugs such as chemotherapeutic agents and which may possess one, two, or more of the properties of an ideal embolizing agent described above.
- the embolizing agents are injectable as a liquid, able to penetrate into the smallest arteries, and transform to an insoluble gel in-situ forming a substantially durable occlusion.
- the embolizing liquids are completely aqueous and compatible with drugs and biotherapeutics thus enabling their localized controlled release.
- the compositions are even compatible with live cells.
- the embolic agents are composed of the protein polymer, silk-elastin-like protein (SELP), a class of genetically engineered protein polymers which have been investigated for use in several different applications.
- SELP silk-elastin-like protein
- SELPs are made up of repeating “blocks” of amino acids, referred to as “silk blocks” (Gly-Ala-Gly-Ala-Gly-Ser) (SEQ ID NO: 1) and “elastin blocks”(Gly-Val-Gly-Val-Pro) (SEQ ID NO: 2).
- the silk blocks consist of the sequence Gly-Ala-Gly-Ala-Gly-Ser (SEQ ID NO: 1), and are based on the naturally occurring fibrillar silk of b. mori , the common silkworm.
- the design of the elastin blocks is based on mammalian elastin, a very common connective tissue in the body which gives skin its elasticity.
- SELPs transform from a liquid at room temperature (approximately 18-23° C.) to a physically cross-linked hydrogel network at body temperature (approximately 37° C.).
- SELPs have been described previously, including in PCT publication no. WO 2013/181471, which is incorporated herein by reference in its entirety.
- the viscosity and gelation rate of the SELP fluids are adjusted by specifying the composition and the concentration of the SELPs.
- the physical properties of the hydrogels, their polymer network densities and its stiffness, can be controlled by the SELP compositions (the silk to elastin ratio and the length of the silk and elastin block domains) and their solution concentrations.
- FIG. 1A illustrates the amino acid sequences of SELP-47K and SELP-815K, two embodiments of SELPs that may comprise the chemoembolics as disclosed herein.
- the silk units forming the rigid backbone are in grey font and the flexible elastin units are shown underlined and in grey font.
- the elastin units allow pore formation which is required for drug release.
- FIG. 1B illustrates the assumed network configurations of SELP-47K and SELP-815K. As shown in FIG. 1B , the pore size of SELP-815K is larger than that of SELP-47K.
- the size of the one or more chemotherapeutic molecule intended to be included in the chemoembolic agents may impact the optimal pore size for the hydrogels and, consequently, the optimal SELP compositions for drug delivery.
- SELP structure In addition to SELP structure, pore size of the network is affected by the concentration of the polymer. Therefore, both SELP structure and concentration can be optimized for drug release by adjusting either the choice of SELP polymer, its concentration, or both. In addition, the pore size, and thus the drug release rate, may be adjusted by blending different SELPs in combination. For example, a mixture of SELP-47K and SELP-815K may release a combination of low and high molecular weight drugs more effectively than either polymer alone.
- FIGS. 2A , 2 B, and 2 C illustrate a schematic of an embodiment of the methods of the present disclosure.
- FIG. 2A illustrates the step of gaining vascular access using an endovascular catheter 102 .
- FIG. 2A illustrates the step of gaining vascular access using an endovascular catheter 102 .
- FIG. 2B illustrates the step of identifying and selecting the artery 104 in the liver 106 that feeds the tumor 108 .
- the chemoembolic agent 110 will be injected into this artery 104 .
- FIG. 2C illustrates the step of administering the chemoembolic agent 110 that comprises a drug or cocktail of drugs by injecting the chemoembolic agent 110 into the tumor vasculature through the selected artery 104 .
- the tip 112 of the endovascular catheter 102 is shown within the selected artery 104 that feeds the tumor 108 .
- the present disclosure provides methods of treating cancer comprising the step of injecting a chemoembolic agent into the vasculature of a subject in need thereof using techniques including, but not limited to, that illustrated in FIGS. 2A , 2 B, and 2 C.
- the methods include a method of treating a cancer, wherein the cancer is hepatocellular carcinoma.
- the method may include the step of injecting a chemoembolic agent, wherein the at least one chemotherapeutic agent is effective against hepatocellular carcinoma.
- the SELP embolic agent is administered without chemotherapeutic agents or cocktails thereof. Because the SELPs in the disclosed agents are biodegradable, the agents may be administered repeatedly. Each time the embolic agent is administered, it may either include one or more chemotherapeutic agents or exclude such agents. In some embodiments, the steps of the disclosed method may alternate between administration of an embolic agent with one or more chemotherapeutic agents and administration of an embolic agent without a chemotherapeutic agent. Additionally, the one or more chemotherapeutic agents that comprise the chemoembolic agent may vary with each administration.
- Embolization with SELPs may offer important advantages over the use of existing embolic agents.
- SELPs are proteins composed solely of natural amino acids and they will ultimately degrade to their constituent amino acids, which are non-toxic and biocompatible.
- the SELP formulations disclosed herein transition from liquids upon injection at room temperature (approximately 18-23° C.) to elastic hydrogels at body temperature (approximately 37° C.), forming stable biomaterials. The transition is not associated with any thermal release, nor is there a change of volume.
- the transition does not involve any chemical reaction, thus there is no possibility of chemically altering the chemotherapeutic agent(s).
- SELPs may be injected through finer catheters, enabling access to distal tumor-specific arteries. This increased precision of transcatheter delivery using a SELP liquid embolic may translate into more selective embolizations, potentially reducing collateral damage to the healthy tissue. Consequently, the novel TACE treatment disclosed herein may be applicable to a greater number of patients, including those with a greater number of tumors and/or greater tumor size than those currently treated with TACE.
- the SELP hydrogels eventually biodegrade, enabling subsequent TACE treatments, if necessary.
- This disclosure also provides a method to further improve the drug delivery capability of SELPs by adding one or more matrix metalloprotease (MMP)-responsive peptide sequences to the monomer unit.
- Drug delivery rate is proportional to the rate the SELP polymer degrades.
- Adding MMP-responsive sequences may increase the rate of SELP polymer degradation and, thus, increase the drug delivery rate when the chemoembolic agent reaches the tumor.
- MMPs are a family of structurally-related endopeptidases, which exist in a dynamic balance with tissue inhibitors of metalloproteases (TIMPs) to control myriad biological functions requiring extracellular matrix degradation. Proper function and regulation of MMPs is responsible for diverse biological functions such as angiogenesis, embryonic development, and wound healing. There are over 20 known specific MMPs, divided into subgroups based on their additional domains and known biological functions.
- the main classes of MMPs are collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and other unclassified MMPs.
- MMPs-2 and -9 are known as gelatinase type A and B, respectively, due to their known ability to degrade gelatin (denatured collagen).
- MMPs-2 and -9 contribute to many processes involving cell migration and signaling, including, for example, angiogenesis and inflammation/innate immunity.
- these MMPs have also been shown to be overexpressed in certain disease states relative to their expression in healthy tissue.
- the expression and activity of MMPs are increased in almost every type of human cancer, and this correlates with advanced tumor stage, increased invasion and metastasis, and shortened survival.
- HCC cells have been shown to produce MMPs including, but not limited to, MMPs-2 and -9.
- the one or more MMP-specific cleavage sites may be chosen to correspond to the enzyme expressed by the relevant tumor.
- the sequence of each MMP-specific cleavage site will depend on the relevant MMP, regardless of the protein polymer used, and may be inserted in advantageous locations within the protein polymers.
- the chemoembolic agent is a SELP-815K copolymer including MMP cleavage sites.
- the one or more MMP cleavage sites in the SELP-815K protein polymer may comprise a cleavage site of either MMP-2, MMP-9, or of both MMP-2 and MMP-9.
- the SELP copolymer comprises the following structure with the MMP-responsive sequence indicated by bold font:
- FIG. 3 presents a flowchart that shows the steps that may be taken to determine a candidate formulation of the chemoembolic agent as disclosed herein.
- the flowchart also includes steps that may be used to move the chemoembolic through feasibility testing of occlusive abilities.
- FIG. 3 also discloses steps that may be used to determine the drug delivery capabilities of the chemoembolic agent.
- Phase I is designed to demonstrate the feasibility of a particular SELP formulation as an effective embolizing agent.
- Phase I begins with steps to be taken to identify SELP copolymer candidates that include (1) testing viscosity of varying concentrations of the SELPs to determine whether they may be injectable through a catheter, (2) rheological characterization to assess gelation time and gel stiffness so as to assess their ability to remain liquid at room temperature and transform to a transarterial embolism at body temperature, and (3) directly testing the feasibility in an in vitro system that mimics the vasculature.
- SELP solutions that are identified as candidates after being tested in Phase I proceed to Phase II, which is designed to test the ability of SELP formulations to deliver drugs to tumors.
- Phase II the manufacturing process of the selected SELP will be scaled up, the formulation optimized, product sterilization and packaging optimized, and drug release profiles evaluated. Implant safety and performance studies in suitable animal models may also be conducted.
- the disclosure also describes a kit that may provide the components of the embolic and/or chemoembolic disclosed herein.
- the kit may comprise a SELP copolymer that is formulated to be used as an embolic as disclosed herein.
- One or more chemotherapeutic compounds may also be included in the kit.
- the SELP copolymer may be provided in liquid form or provided as a freeze dried or lyophilized powder along with a vial or ampoule of sterile water for reconstitution.
- the chemotherapeutic agent may also be provided in liquid form or provided as a freeze dried or lyophilized powder along with a vial or ampoule of sterile water for reconstitution.
- the SELP formulation and the one or more chemotherapeutic agents may be provided in the same or separate containers.
- a microcatheter for use in injection may be provided as may instructions for use of the kit.
- SELP-47K and SELP-815K copolymers used in the following examples were synthesized according to methods known in the art. While the examples disclosed herein characterize the use of SELP-47K and SELP-815K for use as chemoembolics, one of skill in the art will understand that these are but two embodiments of the protein polymers according to the present disclosure that may be formulated for use as embolics and/or chemoembolics.
- Viscosity of the SELPs was determined using an AR 550 stress-controlled rheometer (TA Instruments, New Castle, Del.) with a cone-and-plate configuration using a 20 mm diameter, 4 degree cone.
- SELP copolymers were dissolved in phosphate buffered saline (PBS) at concentrations of 12%, 16%, 18%, or 20% w/w.
- PBS phosphate buffered saline
- the polymer solutions were mixed via vortex and manual inversion incrementally with cooling in ice every 30 s until dissolved (3-4 min.), followed by centrifugation at for 3 minutes at high speed in a clinical centrifuge (International Equipment Co.). Prepared polymer solutions were kept on ice until transfer to the Peltier plate of the rheometer.
- the elapsed time from which the PBS was added to the protein to the time in which the rheometer was started was about 30 to 45 minutes.
- a temperature ramp method was run starting at 1.5° C. and ending at 50° C., duration of 15 min and controlled angular velocity of 6.283 rad/s.
- FIG. 4A illustrates the effect of temperature and concentration on viscosity of SELP-815K. Viscosity levels that are compatible with injection were determined using silicone oil standards injected manually through 2.8° F. microcatheters using 1 cc and 3 cc syringes. Viscosity of all formulations increased as the temperature approached 37° C. The ideal viscosity is that which is injectable through a catheter of a desired size. A less viscous formulation may be injectable through a larger catheter. The viscosity of the formulation is optimally less than 1000 cP at room temperature (18-23° C.). A formulation of less than 500 cP may be used in situations where, for example, a somewhat smaller injection catheter is employed.
- FIG. 4B A rheometer evaluation was conducted to determine if the viscosity of a SELP-47K solution could be obtained in the range suitable for catheter injection. The results of this experiment are shown in FIG. 4B .
- the viscosity of a 12% w/w SELP-47K solution for injection through a 1 m length ⁇ 0.5 mm internal diameter intravascular catheter using a 1 cc syringe with moderate hand pressure was determined empirically to be 50 cP.
- the viscosity increased rapidly following the temperature shift but remained ⁇ 50 cP for 4.8 minutes afterwards.
- the catheter had a hold -up volume of approximately 200 ⁇ l.
- the fluid residence time in the catheter would typically be 2 minutes. Therefore, the fluid in-transit through the catheter at 37° C. would remain fluid and injectable at a viscosity ⁇ 50 cP throughout an anticipated 30-minute injection process.
- FIG. 4C illustrates the results of an experiment that was conducted to assess gel stiffness (G′) of varying concentrations of SELP-815K over time as it formed a hydrogel.
- a rheometer evaluation was conducted as in Example 1 to assess the strength of hydrogels formed from SELP-815K at concentrations of 12, 16, or 20% w/w.
- Oscillatory time sweeps were performed on each sample consisting of an equilibration time sweep at 23° C. and angular frequency of 6.283 rad/s and 1.0% strain for 1 minute followed by a 16 hour sweep at 37° C. and angular frequency of 6.283 rad/s and 0.1% strain.
- SELP concentration was determined by measuring the solution viscosity of SELP-47K at various concentrations ranging from 7.5 to 20% w/w. Viscosity was measured as described in Example 1. The storage modulus (G′) for each sample was measured as a function of time at 37° C. This concentration range yielded SELP-47K solutions that are injectable through hypodermic needles and that undergo hydrogel formation ( FIG. 4D ).
- the embolic and/or chemoembolic solutions will be injected into a tumor vasculature using a transarterial microcatheter. Contrast agent may be added to the solutions to guide the transarterial catheter during this process. Consequently, in some methods, SELP formulations that retain their gel strength when mixed with contrast agent are desirable.
- a solution of SELP-815K at a concentration of 16% w/w was prepared. Contrast agent was added to one sample of the solution at a concentration of 20% w/w contrast agent. The stiffness of the SELP-815K solution with and without contrast agent was assessed as in Example 3.
- FIG. 5 depicts a graph that demonstrates the incorporation of contrast agent into 16% w/w SELP 815K and its impact on gel stiffness.
- the gel formed from the SELP-815K solution that included contrast agent was similar in stiffness to that formed from SELP-815K solution without contrast agent. Consequently, the SELP-815K formulation tested is compatible with the addition of contrast agent for use in guiding the transarterial catheter during embolic and/or chemoembolic agent administration.
- FIG. 6A illustrates the geometry of the microfluidic device.
- the device has two entry ports 610 , a Luer Lok port for injection of the SELP test solution using a syringe 620 and microcatheter 640 and a second entry port for delivery of saline via a syringe pump 630 (see FIG. 6A ).
- the delivery channels merge and enter the occlusion channel at the proximal end.
- a pressure gauge monitored the internal hydrostatic pressure.
- the experiment was conducted to verify that the SELP solutions have sufficient viscosity to prevent their flow through the occlusion channel.
- Three devices were connected in parallel as described above were set up to create a low pressure system mimicking hepatic vasculature. Colored saline designed to simulate blood was injected into one system at a rate of 3.4 ml/min. Internal hydrostatic pressure was maintained below 20 mm Hg. The fluid was able to permeate through the devices without blockage (see FIG. 6B , note that no SELP solution has entered the system as indicated by the detached microcatheter 640 ). The second device was injected with SELP-815K using syringe 620 and microcatheter 640 (see FIG. 6C ) under flow conditions.
- the SELP-815K solution gelled, and blocked flow of the colored saline.
- the SELP hydrogel effectively blocked the solution from proceeding through the system ( FIG. 6C ). This result suggests that the SELP-815K solution (16% w/w) is sufficient to embolize small arteries such as those within tumor vasculature.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 61/848,673 filed Jan. 8, 2013, which is incorporated herein by reference in its entirety.
- The present disclosure relates generally to the field of treating cancer by blocking tumor vasculature with a protein hydrogel embolic agent that may also include a chemotherapeutic drug. The hydrogel may be configured to release chemotherapeutic drug into the tumor at a defined rate.
-
FIG. 1A provides the amino acid sequence of two embodiments of SELPs as disclosed herein, SELP-47K and SELP-815K. -
FIG. 1B illustrates the assumed network configuration of the SELPs ofFIG. 1A . -
FIGS. 2A , 2B, and 2C, together, present a schematic depicting TACE treatment in a subject. -
FIG. 2A illustrates the step of gaining vascular access in the subject. -
FIG. 2B illustrates the step of selecting an artery that feeds the tumor for injecting the chemoembolic agent. -
FIG. 2C illustrates the step of administering the chemoembolic to the tumor. -
FIG. 3 depicts a flowchart that defines steps of a proposed method to identify and test a candidate formulation for a chemoembolic as disclosed herein. -
FIG. 4A is a graph that illustrates the viscosity profiles of different concentrations of SELP-815K. -
FIG. 4B illustrates the viscosity of 12% w/w SELP-47K during a thermal profile that simulated transcatheter injection. -
FIG. 4C is a graph that illustrates the gel stiffness of varying concentrations of SELP-815K over time as it forms a hydrogel. -
FIG. 4D is a graph that illustrates the gelation rates of varying concentrations of SELP-47K over time as they form hydrogels at 37° C. -
FIG. 5 is a graph that demonstrates the incorporation of contrast agent into 16% w/w SELP-815K for use in guiding a transarterial catheter during administration of the embolic agent. -
FIGS. 6A , 6B, and 6C illustrate the in vitro microfluidic system used to assess the ability of the embolic agent to occlude the microvasculature. -
FIG. 6A depicts the in vitro microfluidic device with simulated blood flowing through the structures that simulate the vasculature. -
FIG. 6B depicts the in vitro microfluidic device ofFIG. 6A being injected with SELP-815K solution. -
FIG. 6C depicts the in vitro microfluidic device ofFIG. 6B being injected with simulated blood after injected SELP-815K has formed a hydrogel embolism. - The present disclosure relates generally to the field of embolics and drug delivery methods for treating cancer. More specifically, the present disclosure relates to the use of recombinantly synthesized silk-elastin-like protein (SELP) copolymers to embolize tumor vasculature, including the small vessels such as arterioles. The SELP solution is an injectable liquid at room temperature and forms a hydrogel in the tumor vasculature at body temperature. The material may be loaded with one or more chemotherapeutic drugs which may be released into the tumor from the embolic agent. The copolymers may also have matrix metalloprotease cleavage sites engineered into the protein copolymer using recombinant techniques to enable controlled breakdown of the embolic material. This modification provides control over the duration of embolization and controlled release of the chemotherapeutic agent. Therefore, the material may attack the tumor both by depriving it of blood supply and/or by delivering chemotherapeutic compounds.
- Hepatocellular carcinoma (HCC) is a cancer of the liver which, due to its relative lack of symptoms, is detected at advanced stages in 84% of cases. The 1-year survival rate of symptomatic HCC patients is 22% and at 5 years it is 5%. For these patients, the only curative option is surgical liver resection and liver transplantation. The lack of donor livers and the rapid progression of the disease, however, eliminates this option for most patients.
- Several palliative treatment options can slow the progression of HCC and increase the survival time of patients. Because HCC is generally unresponsive to systemic chemotherapy, localized treatments such as local chemotherapy, radiotherapy, or ablative therapy are typically employed. The most widely used is transcatheter arterial chemoemobolization (TACE). Using endovascular catheters to selectively access the arteries in the liver under radiographic imaging, the objectives of TACE are: 1) to deliver an embolizing agent to the arteries of the tumor(s), selectively blocking blood flow and causing ischemic necrosis, and 2) to co-deliver a chemotherapeutic agent or cocktail of agents, which concentrate in the tumor.
- While TACE is the recommended first-line treatment option to increase survival times of patients with unresectable HCC, its effectiveness is dependent on a number of factors. Foremost among these factors is the physical and chemical nature of the embolizing agent. Liquid embolizing agents are the most easily injected through the smallest diameter catheters, consequently accessing the smaller, more tumor-selective arteries. Their drawback, at times, is that they may not be stably maintained in the arteries as liquids after injection as in the case of Lipiodol®, an iodized esterified oil, or as insoluble masses, as in the case of Onyx®, a liquid suspension of polyethylenevinylalcohol dissolved in DMSO. Embolizing agents consisting of particulate solids form more stable emboli, but are often more difficult to inject. They may require larger diameter catheters due to their large size (typically 200-1000 μm diameter particles), which limits the selectivity of the embolization.
- TACE has been used to treat HCC with some success. However, there are several limitations to the current state of this technique. Collateral damage to healthy liver can arise from excessive non-tumor selective embolization or chemotherapeutic toxicity. For this reason, TACE is contraindicated for treatment of patients with multiple tumors (>2 tumors) or large tumors (>3 cm diameter). Such damage could be avoided and TACE treatment offered to more patients if embolization could be more selectively performed and chemotherapeutic delivery better controlled. Moreover, advances in the understanding of the physiology and pharmacology of hepatocellular carcinoma have led to the development of new potential drug therapies targeting the vascularization of HCC tumors. Attractive among these are the anti-angiogenic drugs targeting vascular endothelial growth factor, VEGF, and its receptor. However, these include high molecular weight therapeutics which cannot be effectively delivered using existing embolizing agents. An example is the biologic, bevacizumab, an anti-VEGF monoclonal antibody, which has a molecular weight of approximately 149 kD. An embolizing agent that is compatible with these drugs and capable of providing sustained delivery of high-molecular weight agents is needed.
- Another factor affecting the efficacy of TACE is the duration of embolization. Ischemic necrosis as a result of embolization is important in controlling tumor growth. Using embolic agents composed of the synthetic polymers polyvinyl alcohol (PVA) or ethylene vinyl acetate (EVA) provides a permanent embolization. These polymers are non-degradable and can remain in tissues indefinitely. If an effective occlusion occurs immediately upon embolization and the occlusion is physically maintained (lack of recanalization), then blood flow to the target tissue will be permanently blocked. However, clinical outcomes are seldom clear-cut. After TACE, tumors have been found to respond to treatment for periods of up to several weeks to months, and then resume growth. Regardless of the reason, the opportunity to retreat a patient that experiences tumor rebound is the hallmark of sustained cancer treatment. Especially for unresectable HCC, which inherently responds poorly to systemic chemotherapy and for which retreatment options are limited, the blockage of blood flow from a previous TACE procedure further restricts these options in that intravascular access to the rebounding tumor is blocked. Restored blood flow to a previously embolized tumor in a treatment-relevant fashion would be clinically beneficial in treating unresectable HCC.
- To be effective, an embolizing agent must be able to be selectively delivered to tumor arteries where it forms stable arterial occlusions. Ideal embolizing agents would likely take the form of a liquid with a viscosity low enough for injection through the smallest endovascular catheters (in some instances ≦500 μm inner diameter), enabling its flow into the smallest arteries, but high enough to restrict its flow through the capillaries and into systemic circulation. After injection, such liquid embolizing agents would transition to a solid hydrogel with enough physical strength to prevent its wash-out into the venous blood flow.
- Such liquid embolizing agents and their hydrogels would also, ideally, be completely aqueous and compatible with the delivery of anti-cancer drugs, including high-molecular-weight biotherapeutics, which are unable to be effectively delivered with current drug-eluting embolizing agents. Localized delivery to the tumor is important because therapeutics that effectively treat HCC and other tumors also often have undesired effects on other tissues. For example, new anti-angiogenic agents suppress tumor revascularization and regrowth, but may also suppress wound healing responses in patients with underlying wound pathologies such as extremity wounds in diabetic patients. Potent anti-proliferative drugs that target cells experiencing hypoxia could have significant effects on embolized liver tumors, however, they may also exacerbate the deterioration of heart and vascular tissues in patients with cardiovascular disease. Avoiding the off-target effects of these and other drugs by concentrating and localizing their release by delivering TACE according to the present disclosure could significantly advance new therapeutic options for HCC.
- Novel arterial embolizing agents are disclosed herein which may elute drugs such as chemotherapeutic agents and which may possess one, two, or more of the properties of an ideal embolizing agent described above. The embolizing agents are injectable as a liquid, able to penetrate into the smallest arteries, and transform to an insoluble gel in-situ forming a substantially durable occlusion. The embolizing liquids are completely aqueous and compatible with drugs and biotherapeutics thus enabling their localized controlled release. The compositions are even compatible with live cells. The embolic agents are composed of the protein polymer, silk-elastin-like protein (SELP), a class of genetically engineered protein polymers which have been investigated for use in several different applications. SELPs are made up of repeating “blocks” of amino acids, referred to as “silk blocks” (Gly-Ala-Gly-Ala-Gly-Ser) (SEQ ID NO: 1) and “elastin blocks”(Gly-Val-Gly-Val-Pro) (SEQ ID NO: 2). The silk blocks consist of the sequence Gly-Ala-Gly-Ala-Gly-Ser (SEQ ID NO: 1), and are based on the naturally occurring fibrillar silk of b. mori, the common silkworm.
- The design of the elastin blocks is based on mammalian elastin, a very common connective tissue in the body which gives skin its elasticity. With appropriate sequence and composition, SELPs transform from a liquid at room temperature (approximately 18-23° C.) to a physically cross-linked hydrogel network at body temperature (approximately 37° C.). SELPs have been described previously, including in PCT publication no. WO 2013/181471, which is incorporated herein by reference in its entirety. The viscosity and gelation rate of the SELP fluids are adjusted by specifying the composition and the concentration of the SELPs. The physical properties of the hydrogels, their polymer network densities and its stiffness, can be controlled by the SELP compositions (the silk to elastin ratio and the length of the silk and elastin block domains) and their solution concentrations.
-
FIG. 1A illustrates the amino acid sequences of SELP-47K and SELP-815K, two embodiments of SELPs that may comprise the chemoembolics as disclosed herein. The silk units forming the rigid backbone are in grey font and the flexible elastin units are shown underlined and in grey font. The elastin units allow pore formation which is required for drug release.FIG. 1B illustrates the assumed network configurations of SELP-47K and SELP-815K. As shown inFIG. 1B , the pore size of SELP-815K is larger than that of SELP-47K. Because pores size impacts the rate of drug release from the polymer, the size of the one or more chemotherapeutic molecule intended to be included in the chemoembolic agents may impact the optimal pore size for the hydrogels and, consequently, the optimal SELP compositions for drug delivery. - In addition to SELP structure, pore size of the network is affected by the concentration of the polymer. Therefore, both SELP structure and concentration can be optimized for drug release by adjusting either the choice of SELP polymer, its concentration, or both. In addition, the pore size, and thus the drug release rate, may be adjusted by blending different SELPs in combination. For example, a mixture of SELP-47K and SELP-815K may release a combination of low and high molecular weight drugs more effectively than either polymer alone.
- In addition, the present disclosure describes novel therapeutic methods comprising the steps of using endovascular catheters to selectively access the arteries in the tumor tissue under radiographic imaging, delivering the embolizing agents and/or chemoembolizing agents to the arteries of the tumor(s) by injecting the agent into the tumor vasculature, thus, selectively blocking blood flow causing ischemic necrosis, and, optionally, co-delivering a chemotherapeutic agent or cocktail of agents, which concentrate in the tumor(s).
FIGS. 2A , 2B, and 2C illustrate a schematic of an embodiment of the methods of the present disclosure.FIG. 2A illustrates the step of gaining vascular access using anendovascular catheter 102.FIG. 2B illustrates the step of identifying and selecting theartery 104 in theliver 106 that feeds thetumor 108. Thechemoembolic agent 110 will be injected into thisartery 104.FIG. 2C illustrates the step of administering thechemoembolic agent 110 that comprises a drug or cocktail of drugs by injecting thechemoembolic agent 110 into the tumor vasculature through the selectedartery 104. Thetip 112 of theendovascular catheter 102 is shown within the selectedartery 104 that feeds thetumor 108. - The present disclosure provides methods of treating cancer comprising the step of injecting a chemoembolic agent into the vasculature of a subject in need thereof using techniques including, but not limited to, that illustrated in
FIGS. 2A , 2B, and 2C. The methods include a method of treating a cancer, wherein the cancer is hepatocellular carcinoma. Furthermore, the method may include the step of injecting a chemoembolic agent, wherein the at least one chemotherapeutic agent is effective against hepatocellular carcinoma. - In an alternative embodiment of the method illustrated in
FIGS. 2A , 2B, and 2C, the SELP embolic agent is administered without chemotherapeutic agents or cocktails thereof. Because the SELPs in the disclosed agents are biodegradable, the agents may be administered repeatedly. Each time the embolic agent is administered, it may either include one or more chemotherapeutic agents or exclude such agents. In some embodiments, the steps of the disclosed method may alternate between administration of an embolic agent with one or more chemotherapeutic agents and administration of an embolic agent without a chemotherapeutic agent. Additionally, the one or more chemotherapeutic agents that comprise the chemoembolic agent may vary with each administration. - Embolization with SELPs may offer important advantages over the use of existing embolic agents. Unlike products composed of synthetic polymers, SELPs are proteins composed solely of natural amino acids and they will ultimately degrade to their constituent amino acids, which are non-toxic and biocompatible. Unlike the currently-available liquid embolics, such as Lipiodol® and Onyx®, the SELP formulations disclosed herein transition from liquids upon injection at room temperature (approximately 18-23° C.) to elastic hydrogels at body temperature (approximately 37° C.), forming stable biomaterials. The transition is not associated with any thermal release, nor is there a change of volume. Furthermore, the transition does not involve any chemical reaction, thus there is no possibility of chemically altering the chemotherapeutic agent(s). Unlike currently-available preformed particles, SELPs may be injected through finer catheters, enabling access to distal tumor-specific arteries. This increased precision of transcatheter delivery using a SELP liquid embolic may translate into more selective embolizations, potentially reducing collateral damage to the healthy tissue. Consequently, the novel TACE treatment disclosed herein may be applicable to a greater number of patients, including those with a greater number of tumors and/or greater tumor size than those currently treated with TACE. Furthermore, the SELP hydrogels eventually biodegrade, enabling subsequent TACE treatments, if necessary.
- This disclosure also provides a method to further improve the drug delivery capability of SELPs by adding one or more matrix metalloprotease (MMP)-responsive peptide sequences to the monomer unit. Drug delivery rate is proportional to the rate the SELP polymer degrades. Adding MMP-responsive sequences may increase the rate of SELP polymer degradation and, thus, increase the drug delivery rate when the chemoembolic agent reaches the tumor.
- MMPs are a family of structurally-related endopeptidases, which exist in a dynamic balance with tissue inhibitors of metalloproteases (TIMPs) to control myriad biological functions requiring extracellular matrix degradation. Proper function and regulation of MMPs is responsible for diverse biological functions such as angiogenesis, embryonic development, and wound healing. There are over 20 known specific MMPs, divided into subgroups based on their additional domains and known biological functions. The main classes of MMPs are collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and other unclassified MMPs.
- MMPs-2 and -9 are known as gelatinase type A and B, respectively, due to their known ability to degrade gelatin (denatured collagen). In normal situations, MMPs-2 and -9 contribute to many processes involving cell migration and signaling, including, for example, angiogenesis and inflammation/innate immunity. However, these MMPs have also been shown to be overexpressed in certain disease states relative to their expression in healthy tissue. The expression and activity of MMPs are increased in almost every type of human cancer, and this correlates with advanced tumor stage, increased invasion and metastasis, and shortened survival. HCC cells have been shown to produce MMPs including, but not limited to, MMPs-2 and -9.
- The one or more MMP-specific cleavage sites may be chosen to correspond to the enzyme expressed by the relevant tumor. The sequence of each MMP-specific cleavage site will depend on the relevant MMP, regardless of the protein polymer used, and may be inserted in advantageous locations within the protein polymers.
- In one embodiment of the disclosure, the chemoembolic agent is a SELP-815K copolymer including MMP cleavage sites. The one or more MMP cleavage sites in the SELP-815K protein polymer may comprise a cleavage site of either MMP-2, MMP-9, or of both MMP-2 and MMP-9. In some embodiments of the chemoembolic agent, the SELP copolymer comprises the following structure with the MMP-responsive sequence indicated by bold font:
-
(SEQ ID NO: 5) [GAGS(GAGAGS)2(GVGVP)3 GVGGPQGIFGQPGKGVP(GVGVP)11 (GAGAGS)5GA]6. - Various embodiments of the disclosed protein polymer are within the scope of this disclosure.
FIG. 3 presents a flowchart that shows the steps that may be taken to determine a candidate formulation of the chemoembolic agent as disclosed herein. The flowchart also includes steps that may be used to move the chemoembolic through feasibility testing of occlusive abilities.FIG. 3 also discloses steps that may be used to determine the drug delivery capabilities of the chemoembolic agent. - The method depicted in
FIG. 3 comprises two phases. Phase I is designed to demonstrate the feasibility of a particular SELP formulation as an effective embolizing agent. Phase I begins with steps to be taken to identify SELP copolymer candidates that include (1) testing viscosity of varying concentrations of the SELPs to determine whether they may be injectable through a catheter, (2) rheological characterization to assess gelation time and gel stiffness so as to assess their ability to remain liquid at room temperature and transform to a transarterial embolism at body temperature, and (3) directly testing the feasibility in an in vitro system that mimics the vasculature. SELP solutions that are identified as candidates after being tested in Phase I proceed to Phase II, which is designed to test the ability of SELP formulations to deliver drugs to tumors. During Phase II, the manufacturing process of the selected SELP will be scaled up, the formulation optimized, product sterilization and packaging optimized, and drug release profiles evaluated. Implant safety and performance studies in suitable animal models may also be conducted. - The disclosure also describes a kit that may provide the components of the embolic and/or chemoembolic disclosed herein. The kit may comprise a SELP copolymer that is formulated to be used as an embolic as disclosed herein. One or more chemotherapeutic compounds may also be included in the kit. The SELP copolymer may be provided in liquid form or provided as a freeze dried or lyophilized powder along with a vial or ampoule of sterile water for reconstitution. The chemotherapeutic agent may also be provided in liquid form or provided as a freeze dried or lyophilized powder along with a vial or ampoule of sterile water for reconstitution. The SELP formulation and the one or more chemotherapeutic agents may be provided in the same or separate containers. A microcatheter for use in injection may be provided as may instructions for use of the kit.
- The SELP-47K and SELP-815K copolymers used in the following examples were synthesized according to methods known in the art. While the examples disclosed herein characterize the use of SELP-47K and SELP-815K for use as chemoembolics, one of skill in the art will understand that these are but two embodiments of the protein polymers according to the present disclosure that may be formulated for use as embolics and/or chemoembolics.
- Viscosity of SELP-815K Formulations at Increasing Temperatures
- Viscosity of the SELPs was determined using an AR 550 stress-controlled rheometer (TA Instruments, New Castle, Del.) with a cone-and-plate configuration using a 20 mm diameter, 4 degree cone. SELP copolymers were dissolved in phosphate buffered saline (PBS) at concentrations of 12%, 16%, 18%, or 20% w/w. The polymer solutions were mixed via vortex and manual inversion incrementally with cooling in ice every 30 s until dissolved (3-4 min.), followed by centrifugation at for 3 minutes at high speed in a clinical centrifuge (International Equipment Co.). Prepared polymer solutions were kept on ice until transfer to the Peltier plate of the rheometer. Generally, the elapsed time from which the PBS was added to the protein to the time in which the rheometer was started was about 30 to 45 minutes. A temperature ramp method was run starting at 1.5° C. and ending at 50° C., duration of 15 min and controlled angular velocity of 6.283 rad/s.
-
FIG. 4A illustrates the effect of temperature and concentration on viscosity of SELP-815K. Viscosity levels that are compatible with injection were determined using silicone oil standards injected manually through 2.8° F. microcatheters using 1 cc and 3 cc syringes. Viscosity of all formulations increased as the temperature approached 37° C. The ideal viscosity is that which is injectable through a catheter of a desired size. A less viscous formulation may be injectable through a larger catheter. The viscosity of the formulation is optimally less than 1000 cP at room temperature (18-23° C.). A formulation of less than 500 cP may be used in situations where, for example, a somewhat smaller injection catheter is employed. However, it is desirable that the formulation maintain an even less viscous liquid form at room temperature (18-23° C.) in order to be able to pass through a microinjection catheter. Therefore, formulations that demonstrated a viscosity of equal to or less than 150 cP (indicated by the dashed and dotted line inFIG. 4A ) at temperatures of 18-23° C. (identified as the box inFIG. 4A ) were deemed most desirable as injectable embolic materials, at least in procedures employing microinjection catheters. One of skill in the art will readily optimize the viscosity of the liquid for the procedure at hand. As shown inFIG. 4A , solutions of 12, 16, and 18% w/w SELP-815K demonstrated a viscosity of equal to or less than 150 cP at temperatures of 18-23° C. while 20% w/w SELP-815K did not. - Assessment of Suitability of Viscosity of SELP-47K Formulation for Injection through Intravascular Catheter
- A rheometer evaluation was conducted to determine if the viscosity of a SELP-47K solution could be obtained in the range suitable for catheter injection. The results of this experiment are shown in
FIG. 4B . The viscosity of a 12% w/w SELP-47K solution for injection through a 1 m length×0.5 mm internal diameter intravascular catheter using a 1 cc syringe with moderate hand pressure was determined empirically to be 50 cP. Rheometric analysis determined the viscosity of the SELP-47K fluid remained ≦46 cP at room temperature for up to 30 minutes (FIG. 4B , 1 cP=0.001 Pa·s). After 30 minutes, the temperature was shifted from room temperature to 37° C. The viscosity increased rapidly following the temperature shift but remained ≦50 cP for 4.8 minutes afterwards. The catheter had a hold -up volume of approximately 200 μl. At a minimum injection rate of 0.1 ml/min, the fluid residence time in the catheter would typically be 2 minutes. Therefore, the fluid in-transit through the catheter at 37° C. would remain fluid and injectable at a viscosity ≦50 cP throughout an anticipated 30-minute injection process. - Assessment of Stiffness of Gels Formed by Formulations of SELP-815K
-
FIG. 4C illustrates the results of an experiment that was conducted to assess gel stiffness (G′) of varying concentrations of SELP-815K over time as it formed a hydrogel. A rheometer evaluation was conducted as in Example 1 to assess the strength of hydrogels formed from SELP-815K at concentrations of 12, 16, or 20% w/w. Oscillatory time sweeps were performed on each sample consisting of an equilibration time sweep at 23° C. and angular frequency of 6.283 rad/s and 1.0% strain for 1 minute followed by a 16 hour sweep at 37° C. and angular frequency of 6.283 rad/s and 0.1% strain. Briefly, individual polymer samples previously prepared to the correct concentration and kept on ice were immediately transferred to the Peltier plate pre-heated to 23° C. at a volume of 150 μl. The equilibration step ends with a temperature ramp up to 37° C. ranging 30-60 seconds before start of the 16 hour run. The time sweep result in traces for G′ and G″, the storage and loss moduli respectively. The G′ plateau represents dynamic gel strength, formulations of 12 and 16% w/w SELP-815K showed similar stiffness within the time assessed in the experiment. In contrast, 20% w/w SELP-815K formed a more stiff gel. This experiment demonstrates that the stiffness of the hydrogels formed by the SELP solutions may be modified and optimized by varying the concentration of the solutions. - Assessment of Relationship between SELP Concentration and Solution Viscosity
- The relationship between SELP concentration and solution viscosity as it relates to catheter injectability was determined by measuring the solution viscosity of SELP-47K at various concentrations ranging from 7.5 to 20% w/w. Viscosity was measured as described in Example 1. The storage modulus (G′) for each sample was measured as a function of time at 37° C. This concentration range yielded SELP-47K solutions that are injectable through hypodermic needles and that undergo hydrogel formation (
FIG. 4D ). - Assessment of Contrast Agent Incorporation into SELP-815K Solution
- During administration, the embolic and/or chemoembolic solutions will be injected into a tumor vasculature using a transarterial microcatheter. Contrast agent may be added to the solutions to guide the transarterial catheter during this process. Consequently, in some methods, SELP formulations that retain their gel strength when mixed with contrast agent are desirable. To assess the effect of contrast agent on gel strength, a solution of SELP-815K at a concentration of 16% w/w was prepared. Contrast agent was added to one sample of the solution at a concentration of 20% w/w contrast agent. The stiffness of the SELP-815K solution with and without contrast agent was assessed as in Example 3.
FIG. 5 depicts a graph that demonstrates the incorporation of contrast agent into 16% w/w SELP 815K and its impact on gel stiffness. The gel formed from the SELP-815K solution that included contrast agent was similar in stiffness to that formed from SELP-815K solution without contrast agent. Consequently, the SELP-815K formulation tested is compatible with the addition of contrast agent for use in guiding the transarterial catheter during embolic and/or chemoembolic agent administration. - In Vitro Evaluation of Embolic Capabilities of SELP-815K
- An in vitro test system was developed to evaluate the performance of a 16% w/w SELP-815K solution in embolization. This system comprised a custom microfluidic device to simulate arterio-capillary geometry and flow. It consists of a tapered occlusion channel with a proximal internal diameter of 1 mm at the entry and a distal internal diameter of 0.05 mm at the center.
FIG. 6A illustrates the geometry of the microfluidic device. The device has twoentry ports 610, a Luer Lok port for injection of the SELP test solution using asyringe 620 andmicrocatheter 640 and a second entry port for delivery of saline via a syringe pump 630 (seeFIG. 6A ). The delivery channels merge and enter the occlusion channel at the proximal end. A pressure gauge monitored the internal hydrostatic pressure. - The experiment was conducted to verify that the SELP solutions have sufficient viscosity to prevent their flow through the occlusion channel. Three devices were connected in parallel as described above were set up to create a low pressure system mimicking hepatic vasculature. Colored saline designed to simulate blood was injected into one system at a rate of 3.4 ml/min. Internal hydrostatic pressure was maintained below 20 mm Hg. The fluid was able to permeate through the devices without blockage (see
FIG. 6B , note that no SELP solution has entered the system as indicated by the detached microcatheter 640). The second device was injected with SELP-815K using syringe 620 and microcatheter 640 (seeFIG. 6C ) under flow conditions. The SELP-815K solution gelled, and blocked flow of the colored saline. The SELP hydrogel effectively blocked the solution from proceeding through the system (FIG. 6C ). This result suggests that the SELP-815K solution (16% w/w) is sufficient to embolize small arteries such as those within tumor vasculature. - All publications cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein and as though fully set forth.
- Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the area can, using the preceding description, utilize the present disclosure to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments disclosed in which an exclusive property or privilege is claimed are defined as follows.
Claims (20)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/150,652 US20140194370A1 (en) | 2013-01-08 | 2014-01-08 | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
US15/064,142 US9932389B2 (en) | 2013-01-08 | 2016-03-08 | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361848673P | 2013-01-08 | 2013-01-08 | |
US14/150,652 US20140194370A1 (en) | 2013-01-08 | 2014-01-08 | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/064,142 Division US9932389B2 (en) | 2013-01-08 | 2016-03-08 | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140194370A1 true US20140194370A1 (en) | 2014-07-10 |
Family
ID=51061416
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/150,652 Abandoned US20140194370A1 (en) | 2013-01-08 | 2014-01-08 | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
US15/064,142 Active US9932389B2 (en) | 2013-01-08 | 2016-03-08 | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/064,142 Active US9932389B2 (en) | 2013-01-08 | 2016-03-08 | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer |
Country Status (1)
Country | Link |
---|---|
US (2) | US20140194370A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150152165A1 (en) * | 2012-05-30 | 2015-06-04 | The University Of Utah Research Foundation | Matrix metalloproteinase cleavable protein polymers for cancer gene therapy |
US20180303886A1 (en) * | 2015-06-19 | 2018-10-25 | Sillajen, Inc. | Compositions and methods for viral embolization |
US10849914B2 (en) | 2017-06-12 | 2020-12-01 | University Of Utah Research Foundation | Methods for producing chemoembolic agents for the delivery of anti-cancer agents |
US20210290790A1 (en) * | 2015-03-12 | 2021-09-23 | Sanyo Chemical Industries, Ltd. | Method for producing protein composition, and protein composition |
US11337994B2 (en) | 2016-09-15 | 2022-05-24 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014031693A1 (en) * | 2012-08-20 | 2014-02-27 | Genelux Corporation | Compositions containing protein polymers and vaccinia virus, and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5606019A (en) | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
CA2319872C (en) | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
DK1355566T3 (en) | 2000-12-18 | 2013-03-04 | Univ Texas | Local regional chemotherapy and radiotherapy using hydrogel in situ |
US20050142094A1 (en) | 2003-03-12 | 2005-06-30 | Manoj Kumar | Use of repeat sequence protein polymers in personal care compositions |
EP1660013A4 (en) | 2003-08-26 | 2011-07-20 | Gel Del Technologies Inc | Protein biomaterials and biocoacervates and methods of making and using thereof |
DK1986611T3 (en) | 2006-02-23 | 2013-07-29 | Danisco Us Inc | Protein polymer nanoparticles with repeat sequence possibly containing active substances and preparation thereof |
US20110189292A1 (en) | 2009-04-20 | 2011-08-04 | Allergan, Inc. | Dermal fillers comprising silk fibroin hydrogels and uses thereof |
US8287840B2 (en) | 2009-07-24 | 2012-10-16 | Abbott Cardiovascular Systems Inc. | Method of treating malignant solid tumors using transcatheter arterial chemoembolization (TACE) |
CN102988274B (en) | 2010-09-08 | 2015-01-28 | 上海市肿瘤研究所 | Sustained-release blood vessel embolic gel used for treating tumor, and preparation method thereof |
KR101384991B1 (en) | 2011-07-18 | 2014-06-17 | 서울대학교산학협력단 | DRUG DELIVERY SYSTEM BASED ON INTERVENTIONAL INJECTION OF TEMPERATURE AND pH-SENSITIVE INJECTABLE HYDROGEL |
WO2013181471A2 (en) | 2012-05-30 | 2013-12-05 | The University Of Utah Research Foundation | Matrix metalloproteinase cleavable protein polymers for cancer gene therapy |
-
2014
- 2014-01-08 US US14/150,652 patent/US20140194370A1/en not_active Abandoned
-
2016
- 2016-03-08 US US15/064,142 patent/US9932389B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014031693A1 (en) * | 2012-08-20 | 2014-02-27 | Genelux Corporation | Compositions containing protein polymers and vaccinia virus, and methods of use thereof |
US20140086976A1 (en) * | 2012-08-20 | 2014-03-27 | Aladar A. Szalay | Compositions containing protein polymers and vaccinia virus, and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
Skjot-Arkil et al. 2012; Measurement of MMP-9 and MMP-12 degraded elastin (ELM) provides unique information on lung tissue degradation. Pulmonary Medicine. 12:34, pages 1-12. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150152165A1 (en) * | 2012-05-30 | 2015-06-04 | The University Of Utah Research Foundation | Matrix metalloproteinase cleavable protein polymers for cancer gene therapy |
US10253089B2 (en) * | 2012-05-30 | 2019-04-09 | University Of Utah Research Foundation | Matrix metalloproteinase cleavable protein polymers for cancer gene therapy |
US20210290790A1 (en) * | 2015-03-12 | 2021-09-23 | Sanyo Chemical Industries, Ltd. | Method for producing protein composition, and protein composition |
US11969512B2 (en) * | 2015-03-12 | 2024-04-30 | Sanyo Chemical Industries, Ltd. | Method for producing protein composition, and protein composition |
US20180303886A1 (en) * | 2015-06-19 | 2018-10-25 | Sillajen, Inc. | Compositions and methods for viral embolization |
US10517910B2 (en) * | 2015-06-19 | 2019-12-31 | Sillajen, Inc. | Compositions and methods for viral embolization |
US11337994B2 (en) | 2016-09-15 | 2022-05-24 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
US10849914B2 (en) | 2017-06-12 | 2020-12-01 | University Of Utah Research Foundation | Methods for producing chemoembolic agents for the delivery of anti-cancer agents |
US20210060037A1 (en) * | 2017-06-12 | 2021-03-04 | University Of Utah Research Foundation | Methods For Producing Chemoembolic Agents For The Delivery Of Anti-Cancer Agents |
Also Published As
Publication number | Publication date |
---|---|
US9932389B2 (en) | 2018-04-03 |
US20160176949A1 (en) | 2016-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9932389B2 (en) | Silk-elastin like protein polymers for embolization and chemoembolization to treat cancer | |
Taki et al. | A new liquid material for embolization of arteriovenous malformations. | |
US5894022A (en) | Embolic material for endovascular occlusion of abnormal vasculature and method of using the same | |
US11426450B2 (en) | Shear-thinning compositions as an intravascular embolic agent | |
Numan et al. | Embolization of peripheral vascular malformations with ethylene vinyl alcohol copolymer (Onyx) | |
JP5542449B2 (en) | Method for modifying myocardial infarction progression | |
ES2968412T3 (en) | Method for preparing a hemostatic composition | |
US20040087930A1 (en) | Methods for embolizing vascular sites with an embolizing composition | |
JP2003500114A (en) | Novel high viscosity embolization composition | |
CN106572973B (en) | Device and method for injectable sclerosant foams using a carrier matrix and uses thereof | |
JP2006247433A (en) | Method for aneurysm repair | |
Kim et al. | Treatment strategies to attenuate perihematomal edema in patients with intracerebral hemorrhage | |
Becker et al. | In vivo assessment of calcium alginate gel for endovascular embolization of a cerebral arteriovenous malformation model using the swine rete mirabile | |
Becker et al. | Calcium alginate gel as a biocompatible material for endovascular arteriovenous malformation embolization: six-month results in an animal model | |
Regine et al. | Embolization of traumatic and non-traumatic peripheral vascular lesions with Onyx | |
US20110218517A1 (en) | In vivo chemical stabilization of vulnerable plaque | |
WO2021046389A1 (en) | Compositions and methods for using silk-elastinlike protein-based polymers | |
CN103432632B (en) | A kind of thermosensitive in situ gel compositions and preparation method | |
Hamada et al. | A nonadhesive liquid embolic agent composed of ethylene vinyl alcohol copolymer and ethanol mixture for the treatment of cerebral arteriovenous malformations: experimental study | |
Alexander et al. | Targeting cerebral arteriovenous malformations for minimally invasive therapy | |
Hamada et al. | A mixture of ethylene vinyl alcohol copolymer and ethanol yielding a nonadhesive liquid embolic agent to treat cerebral arteriovenous malformations: initial clinical experience | |
Ganguli et al. | A water-based liquid embolic: evaluation of its safety and efficacy in A rabbit kidney model | |
Micovic et al. | Novel autologous, high concentrated fibrin as advanced hemostatic agent for coronary surgery | |
Wright et al. | Experimental evaluation of cellulose acetate NF and ethylene-vinyl alcohol copolymer for selective arterial embolization | |
Lewis | Embolisation devices from biomedical polymers for intra-arterial occlusion and drug delivery in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE UNIVERSITY OF UTAH, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAPPELLO, JOSEPH;GHANDEHARI, HAMIDREZA;POURSAID, AZADEH E.;SIGNING DATES FROM 20140129 TO 20140130;REEL/FRAME:032117/0273 Owner name: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE UNIVERSITY OF UTAH;REEL/FRAME:032117/0546 Effective date: 20140131 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF UTAH;REEL/FRAME:035722/0523 Effective date: 20150501 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF UTAH;REEL/FRAME:035786/0274 Effective date: 20150501 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |